Clear Harbor Asset Management LLC Purchases Shares of 3,551 Stryker Corporation $SYK

Posted by George Bondi on Aug 23rd, 2026

Clear Harbor Asset Management LLC acquired a new position in shares of Stryker Corporation (NYSE:SYK – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 3,551 shares of the medical technology company’s stock, valued at approximately $1,118,000.

Other large investors have also made changes to their positions in the company. VanderPol Investments L.L.C. grew its position in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after buying an additional 28 shares in the last quarter. KCM Investment Advisors LLC increased its stake in Stryker by 1.5% during the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after acquiring an additional 28 shares during the period. Rossby Financial LCC raised its holdings in Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after acquiring an additional 28 shares in the last quarter. Tcfg Wealth Management LLC lifted its position in shares of Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares during the period. Finally, ICW Investment Advisors LLC lifted its position in shares of Stryker by 0.6% in the 4th quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock worth $1,791,000 after acquiring an additional 30 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on SYK. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Royal Bank Of Canada reduced their target price on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Evercore set a $350.00 price target on shares of Stryker in a research note on Monday, July 6th. BTIG Research lowered their price target on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Finally, Leerink Partners dropped their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

View Our Latest Analysis on SYK

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Trading Up 0.7%

SYK stock opened at $329.86 on Friday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $326.99 and its 200-day moving average is $332.64. The firm has a market cap of $126.52 billion, a P/E ratio of 34.18, a P/E/G ratio of 2.10 and a beta of 0.76.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Activity

In other news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 665,370 shares of company stock worth $216,238,501. Corporate insiders own 4.60% of the company’s stock.

About Stryker

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.